Resources

Educational resources for the treatment and management of leukemias. Access expert overviews, podcasts, treatment and management guidelines from key clinical centers.

Listen to Dr Elias Jabbour’s and Dr Naval Daver’s experiences on how MD Anderson Cancer Center is managing acute leukemia patients in the era of the COVID-19 pandemic.

Podcast: Managing ALL & AML during COVID-19

View the regimens and supportive care guidelines from centers of excellence

Frontline and R/R ALL regimens at MD Anderson Cancer Center

Protocol ALL-11

View Interesting Presentations From the Experts

“Review of Prognostic Value of MRD in ALL: Why I Call It Measurable Residual Disease”

Elias Jabbour, MD
October, 2019

“Measurable Residual Disease (MRD) Assessment in Adults With Acute Lymphoblastic Leukemia: Methods and Implementation”

Aaron Logan, MD, PhD
October, 2019

“Measurable Residual Disease (MRD) Assessment in Adults with Acute Lymphoblastic Leukemia: Role for MRD in CR1 vs CR2+”

Aaron Logan, MD, PhD
October, 2019

“Frontline Therapies in Adults and Older Patients with ALL”

Elias Jabbour, MD
October, 2019

“Measurable Residual Disease (MRD) Assessment in Adults with Acute Lymphoblastic Leukemia: MRD in AYA/non-elderly ALL”

Aaron Logan, MD, PhD
October, 2019

“MRD in R/R ALL role of transplant”

Elias Jabbour, MD
October, 2019

“Measurable Residual Disease (MRD) Assessment in Adults with Acute Lymphoblastic Leukemia: What Else Do We Need to Learn?”

Aaron Logan, MD, PhD
October, 2019

“AML. Is It Time To Routinely Incorporate MRD Into Practice?”

Elias Jabbour, MD
October, 2019

Expert insights – EPICS Reports

Get insights from global expert discussions on acute leukemias in our Emerging Paradigms in Care Series reports

Expert Commentaries: Leukemia 2019

Expert Commentaries: ASH 2019 – Focus on Acute Leukemia